Publications by authors named "Marta Hamilton"

Claim this Profile
S
Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury.
Segav Demirjian, Gorav Ailawadi, Martin Polinsky, Dani Bitran, Shuli Silberman, Marta Hamilton

Kidney Int Rep· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Heidemarie Kletzl, Mylene Giraudon, Patricia Sanwald Ducray, Markus Abt, Marta Hamilton

Anticancer Drugs· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Hilary Calvert, Chris Twelves, Malcolm Ranson, Ruth Plummer, Scott Fettner, Marta Hamilton

Anticancer Drugs· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.
Marta Hamilton, Julie L Wolf, Daniel W Drolet, Scott H Fettner, Ashok K Rakhit

Cancer Chemother Pharmacol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sith Sathornsumetee, Annick Desjardins, James J Vredenburgh, Roger E McLendon, Jennifer Marcello, Marta Hamilton

Neuro Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Regina I Jakacki, Marta Hamilton, Richard J Gilbertson, Susan M Blaney, Jean Tersak

J Clin Oncol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
Ashok Rakhit, Michael P Pantze, Scott Fettner, Hannah M Jones, Jean-Eric Charoin, Marta Hamilton

Eur J Clin Pharmacol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Tomislav Dragovich, Mark Huberman, Daniel D Von Hoff, Eric K Rowinsky, Paul Nadler, Marta Hamilton

Cancer Chemother Pharmacol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Amita Patnaik, Debra Wood, Anthony W Tolcher, Marta Hamilton, Jeffrey I Kreisberg

Clin Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Jian-Feng Lu, Steve M Eppler, Julie Wolf, Marta Hamilton, Ashok Rakhit

Clin Pharmacol Ther· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of smoking on the pharmacokinetics of erlotinib.
Marta Hamilton, Julie L Wolf, Jason Rusk, Shannon E Beard, Gary M Clark

Clin Cancer Res· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
Jie Ling, Kim A Johnson, Zhuang Miao, Ashok Rakhit, Michael P Pantze, Marta Hamilton

Drug Metab Dispos· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
Paul Frohna, Jianfeng Lu, Steve Eppler, Marta Hamilton, Julie Wolf

J Clin Pharmacol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques.
Koen K A Van Rompay, Marta Hamilton, Brian Kearney, Norbert Bischofberger

Antimicrob Agents Chemother· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Graham G Dark, A Hilary Calvert, Robert Grimshaw, Christopher Poole, Ken Swenerton, Marta Hamilton

J Clin Oncol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
W Jeffrey Petty, Konstantin H Dragnev, Vincent A Memoli, Yan Ma, Neil B Desai, Marta Hamilton

Clin Cancer Res· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.
Koen K A Van Rompay, Laurie L Brignolo, Dennis J Meyer, Christopher Jerome, Ross Tarara, Marta Hamilton

Antimicrob Agents Chemother· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Francis J Giles, Martin S Tallman, Guillermo Garcia-Manero, Jorge E Cortes, Deborah A Thomas, Marta Hamilton

Cancer· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualification of analytical instruments for use in the pharmaceutical industry: a scientific approach.
Surendra K Bansal, Thomas Layloff, Ernest D Bush, Marta Hamilton, Edward A Hankinson

AAPS PharmSciTech· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Diederik F S Kehrer, Annelies M Bos, Jaap Verweij, Harry J Groen, Walter J Loos, Marta Hamilton

J Clin Oncol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
Walter J Loos, Jaap Verweij, Diederik F S Kehrer, Peter de Bruijn, Franciscus M H de Groot, Marta Hamilton

Clin Cancer Res· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis